Jiangsu Nhwa Pharmaceutical Future Growth
Future criteria checks 2/6
Jiangsu Nhwa Pharmaceutical is forecast to grow earnings and revenue by 19.1% and 17.5% per annum respectively. EPS is expected to grow by 19.2% per annum. Return on equity is forecast to be 17.7% in 3 years.
Key information
19.1%
Earnings growth rate
19.2%
EPS growth rate
Pharmaceuticals earnings growth | 18.4% |
Revenue growth rate | 17.5% |
Future return on equity | 17.7% |
Analyst coverage | Good |
Last updated | 05 Aug 2024 |
Recent future growth updates
Recent updates
Here's Why Jiangsu Nhwa Pharmaceutical (SZSE:002262) Has Caught The Eye Of Investors
Jul 22Jiangsu Nhwa Pharmaceutical (SZSE:002262) Seems To Use Debt Rather Sparingly
Jun 16Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Share Price Is Matching Sentiment Around Its Earnings
May 09Jiangsu Nhwa Pharmaceutical (SZSE:002262) Ticks All The Boxes When It Comes To Earnings Growth
Apr 18Earnings Update: Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Apr 02Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 8,346 | 1,791 | N/A | 1,493 | 7 |
12/31/2025 | 6,977 | 1,477 | N/A | 1,290 | 8 |
12/31/2024 | 5,895 | 1,220 | N/A | 1,036 | 7 |
6/30/2024 | 5,405 | 1,121 | 752 | 1,184 | N/A |
3/31/2024 | 5,220 | 1,075 | 529 | 877 | N/A |
12/31/2023 | 5,042 | 1,037 | 634 | 1,008 | N/A |
9/30/2023 | 4,834 | 1,044 | 719 | 1,039 | N/A |
6/30/2023 | 4,698 | 998 | 560 | 911 | N/A |
3/31/2023 | 4,485 | 939 | 585 | 939 | N/A |
1/1/2023 | 4,299 | 901 | 533 | 861 | N/A |
9/30/2022 | 4,164 | 867 | 521 | 813 | N/A |
6/30/2022 | 4,072 | 834 | 537 | 768 | N/A |
3/31/2022 | 4,024 | 819 | 505 | 728 | N/A |
1/1/2022 | 3,936 | 798 | 495 | 701 | N/A |
9/30/2021 | 3,879 | 830 | 914 | 1,194 | N/A |
6/30/2021 | 3,744 | 787 | 880 | 1,171 | N/A |
3/31/2021 | 3,528 | 759 | 981 | 1,270 | N/A |
12/31/2020 | 3,361 | 729 | 980 | 1,248 | N/A |
9/30/2020 | 3,326 | 714 | 149 | 325 | N/A |
6/30/2020 | 3,534 | 694 | 257 | 424 | N/A |
3/31/2020 | 3,837 | 675 | 237 | 397 | N/A |
12/31/2019 | 4,149 | 663 | 146 | 306 | N/A |
9/30/2019 | 4,167 | 623 | 568 | 727 | N/A |
6/30/2019 | 4,090 | 585 | 371 | 518 | N/A |
3/31/2019 | 3,981 | 549 | 341 | 464 | N/A |
12/31/2018 | 3,858 | 525 | 234 | 405 | N/A |
9/30/2018 | 3,764 | 472 | 239 | 431 | N/A |
6/30/2018 | 3,581 | 447 | 267 | 468 | N/A |
3/31/2018 | 3,482 | 411 | N/A | 436 | N/A |
12/31/2017 | 3,394 | 395 | N/A | 452 | N/A |
9/30/2017 | 3,274 | 400 | N/A | 384 | N/A |
6/30/2017 | 3,181 | 347 | N/A | 365 | N/A |
3/31/2017 | 3,097 | 325 | N/A | 361 | N/A |
12/31/2016 | 3,018 | 310 | N/A | 277 | N/A |
9/30/2016 | 3,004 | 297 | N/A | 263 | N/A |
6/30/2016 | 2,937 | 284 | N/A | 230 | N/A |
3/31/2016 | 2,851 | 269 | N/A | 183 | N/A |
12/31/2015 | 2,767 | 258 | N/A | 204 | N/A |
9/30/2015 | 2,694 | 257 | N/A | 140 | N/A |
6/30/2015 | 2,628 | 246 | N/A | 141 | N/A |
3/31/2015 | 2,566 | 235 | N/A | 193 | N/A |
12/31/2014 | 2,501 | 223 | N/A | 160 | N/A |
9/30/2014 | 2,418 | 213 | N/A | 218 | N/A |
6/30/2014 | 2,375 | 201 | N/A | 233 | N/A |
3/31/2014 | 2,310 | 186 | N/A | 204 | N/A |
12/31/2013 | 2,236 | 176 | N/A | 194 | N/A |
9/30/2013 | 2,156 | 169 | N/A | 151 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 002262's forecast earnings growth (19.1% per year) is above the savings rate (2.9%).
Earnings vs Market: 002262's earnings (19.1% per year) are forecast to grow slower than the CN market (22% per year).
High Growth Earnings: 002262's earnings are forecast to grow, but not significantly.
Revenue vs Market: 002262's revenue (17.5% per year) is forecast to grow faster than the CN market (13.5% per year).
High Growth Revenue: 002262's revenue (17.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 002262's Return on Equity is forecast to be low in 3 years time (17.7%).